SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ:AKRO) investors who suffered substantial losses to submit their losses now.
Class Period: Sep. 13, 2022 – Oct. 9, 2023
Lead Plaintiff Deadline: June 25, 2024
Visit: www.hbsslaw.com/investor-fraud/AKRO
Contact the Firm Now: AKRO@hbsslaw.com
844-916-0895
Akero Therapeutics, Inc. (AKRO) Class Action:
Akero Therapeutics, a biopharmaceutical company developing treatments for liver disease, is under fire from investors in a securities class action lawsuit. The lawsuit alleges that Akero misled investors about a key clinical trial designed to evaluate their lead drug candidate efruxifermin.
The trial, called SYMMETRY, investigated efruxifermin's effectiveness in treating nonalcoholic steatohepatitis (NASH). However, the lawsuit ...